Friday 16 October 2026
Export AVXL’s income statement to Excel — free account
Anavex Life Sciences Corp.
AVXL Healthcare Biotechnology
In the quarter to June 2026, EPS grew 150.0% and free cash flow grew 27.0%, each against the same quarter a year earlier.
1.31
0.17
−11.49%
Follow AVXL
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 2.43 | 3.01 | 1.25 | 1.48 | 2.20 | 5.12 | 7.13 | 4.90 | 3.25 | 2.86 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 8.30 | 6.64 | 4.35 | 4.09 | 7.69 | 31.50 | 18.19 | 11.93 | 14.44 | 14.25 | |||||
| People | |||||||||||||||
| People | Employees | 10 | 10 | 13 | 16 | 20 | 25 | 38 | 40 | 42 | 34 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | — | — | — | — | — | — | — | — | — | |||||
| EBT | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (48) | (43) | (46) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (48) | (43) | (46) | |||||
| Depreciation | 0 | — | — | 0 | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (0.42) | (0.33) | (0.39) | (0.54) | (0.45) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) | |||||
| Cash flow | (0.26) | (0.22) | (0.28) | (0.38) | (0.37) | (0.44) | (0.32) | (0.35) | (0.37) | (0.46) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.26) | (0.22) | (0.28) | (0.38) | (0.37) | (0.44) | (0.32) | (0.35) | (0.37) | (0.46) | |||||
| Book value | 0.18 | 0.59 | 0.50 | 0.41 | 0.47 | 2.16 | 1.85 | 1.78 | 1.44 | 1.11 | |||||
| Shares, m | 35 | 41 | 45 | 49 | 58 | 70 | 77 | 80 | 83 | 85 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (9) | (9) | (13) | (19) | (21) | (30) | (24) | (28) | (31) | (39) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | (9) | (9) | (13) | (19) | (21) | (30) | (24) | (28) | (31) | (39) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 6 | 24 | 22 | 20 | 27 | 151 | 142 | 142 | 120 | 95 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | (9) | (27) | (23) | (22) | (29) | (152) | (149) | (151) | (132) | (103) | |||||
| Shareholders’ equity | 6 | 24 | 22 | 20 | 27 | 151 | 142 | 142 | 120 | 95 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (118.04) | (72.10) | (63.85) | (102.05) | (87.79) | (38.65) | (30.53) | (30.94) | (29.66) | (38.75) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (154.17) | (88.09) | (74.08) | (123.42) | (110.59) | (42.58) | (32.71) | (33.41) | (32.81) | (43.11) | |||||
Negative figures in brackets.
Charts ten years each
Anavex Life Sciences Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CDXS Codexis, Inc. | $148.9M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $137.2M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | |
| ANTX AN2 Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $135.6M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TLSA Tiziana Life Sciences Ltd | $134.7M | — (loss-making) | — | — | −258.11% (below 0%: shrinking) | +18.03% (above 0%: growing) | 0.00% | — | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $137.1M | — | — | −50.77% | — | +20.90% | 0.00% | 0.00% |
Anavex Life Sciences Corp. (AVXL) key facts
- Anavex Life Sciences Corp. (AVXL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 15, 2026, AVXL traded at $1.48, a market capitalization of $137.2 million.
- Return on equity was −43.1% and debt-to-equity 0.00.